Iteos Therapeutics, INC Form 4 insider transactions

Director Ann Rhoads acquired 24,200 stock options in iTeos Therapeutics on June 11, 2024.

Director Robert Iannone acquired 24,200 stock options in Iteos Therapeutics, Inc. on June 11, 2024.

Boxer Capital, LLC, along with related entities and individuals, reports a transaction involving the acquisition and disposition of iTeos Therapeutics, Inc. common stock.

RA Capital Management, L.P. reports a transaction involving the exchange of iTeos Therapeutics, Inc. common stock for pre-funded warrants, affecting their beneficial ownership.

Chief Financial Officer of Iteos Therapeutics, Matthew Gall, received stock options for 163,200 shares on March 7, 2024, vesting over four years.

Matthew Call, Chief Operating Officer of Iteos Therapeutics, was granted stock options for 225,000 shares on March 7, 2024.

Yvonne McGrath, Chief Scientific Officer of Iteos Therapeutics, acquired stock options for 153,600 shares of common stock on March 7, 2024.

Michel Detheux, CEO of iTeos Therapeutics, acquired stock options for 590,400 shares on March 7, 2024, vesting over four years.

Director Jill DeSimone acquired 44,766 stock options in Iteos Therapeutics, Inc. on March 7, 2024.